Transgenic Amyloid Models

Test putative Alzheimer’s disease therapeutics using in vivo models with amyloid beta plaque deposition and the downstream pathological events

Home » Neurology Research Models and Services  » Alzheimer’s models and services » Alzheimer’s models – Transgenic Amyloid Models
The histopathological hallmarks of Alzheimer’s disease (AD) are extracellular plaques composed of Amyloid Beta (Aβ) and intracellular inclusions of the protein Tau (neurofibrillary tangles). Cleavage of the amyloid precursor protein (APP) leads to the generation of amyloid beta (Aβ) protein fragments. 

Mouse models of amyloid pathology (over)express the human APP with familial AD-related mutations. These mouse models recapitulate the Aβ aggregation cascade by expressing higher levels of the toxic Aβ1-40 and Aβ1-42 peptides. The biological and associated behavioural deficits observed in amyloid models make them a valuable model of AD, suitable for drug-screening studies.

InnoSer offers unique contract research services using several in vivo AD models, including a range of transgenic Aβ models. Transgenic Aβ models faithfully recapitulate AD’s Aβ plaque pathology. Transgenic Aβ models can be used to study downstream pathological events such as neuroinflammation. As all transgenic models present with amyloid plaques, inflammation and cognitive deficits in different timeframes; the choice of the model depends on experimental compound’s mechanism of action and your research goals.  

Take advantage of InnoSer’s expertise, flexibility and collaborative approach for your research. Our in-house neurology experts have a long-standing experience with modelling AD in vivo and are happy to help guide your decision on choosing the best model fit for your current research goals. 

Transgenic amyloid models that InnoSer offers:

  • APP/PS1 (ARTE10)
  • APPSWE (Tg2576)
  • APPSWE-Tau
  • Humanized APP (APP-SAA Targeted Replacement)

Find the right model for you.

Compare our model capabilities and discover which of our neurology platforms suits your research needs

Belgian based preclinical neurology CRO mouse models

Key readouts

Test the efficacy of your treatments in the following battery of cognitive behavioural tests:

Test the efficacy of your treatments with the following biological readouts: 

  •  MSD: Plasma, CSF, and brain (e.g., Aβ, cytokines, NfL). 
  • (Digital) histopathology 
  • Immunohistochemistry (e.g., Aβ plaques, phosphorylated Tau, microglia & astrocyte activation)
  • Immunofluorescence and FISH 

Related Alzheimer’s disease model options

Neurology Platform Overview

Highly relevant neurology models to facilitate preclinical drug development

Transgenic Tau Models

InnoSer offers unique research services with several different transgenic tau models, which recapitulate the Tau neurofibrillary tangle pathology of AD.

Tau Seeding Model

InnoSer uses an AD brain extract injection model, providing unique preclinical services with a translational model of Tau pathology seeding and spreading.

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.


Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

Need more information?

If you have any questions about how we can help accelerate your research,

then let us know